Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977784 | 0.91 | MEN1 (0.36) | KMT2AMEN1HPGDNPSR1MAPT | |
| SCHEMBL2967671 | 0.90 | KMT2A (0.43) | KMT2AMEN1HPGDNPSR1MAPT | |
| SCHEMBL8636262 | 0.87 | KMT2A (0.46) | KMT2AMEN1HPGDNPSR1MAPT | |
| SCHEMBL3583472 | 0.86 | KMT2A (0.44) | KMT2AMEN1HPGDNPSR1MAPT | |
| SCHEMBL3576339 | 0.84 | KMT2A (0.43) | KMT2AMEN1HPGDNPSR1MAPT | |
| SCHEMBL3580003 | 0.83 | KMT2A (0.42) | KMT2AMEN1HPGDNPSR1MAPT | |
| Dimethylamine SCHEMBL8762457 | 0.83 | KMT2A (0.46) | KMT2AMEN1HPGDNPSR1CYP3A4 | |
| SCHEMBL3586420 | 0.82 | KMT2A (0.40) | KMT2AMEN1HPGDNPSR1MAPT | |
| SCHEMBL3582294 | 0.82 | KMT2A (0.41) | KMT2AMEN1HPGDNPSR1MAPT | |
| SCHEMBL3579178 | 0.82 | KMT2A (0.41) | KMT2AMEN1HPGDNPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776924-B2 | Nitroaniline-based alkylating agents and their use as prodrugs | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-08-17 | — | — | US | disclosed |
| EP-1558568-A4 | NITROANILINE-BASED ALKYLATING AGENTS AND THEIR USE AS PRODRUGS | AUCKLAND UNISERVICES LTD (NZ) | 2006-10-18 | — | — | EP | disclosed |
| US-20050256191-A1 | Nitroaniline-based alkylating agents and their use as prodrugs | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-11-17 | — | — | US | disclosed |
| EP-1558568-A1 | NITROANILINE-BASED ALKYLATING AGENTS AND THEIR USE AS PRODRUGS | Auckland Uniservices Limited (NZ) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004033415-A1 | NITROANILINE-BASED ALKYLATING AGENTS AND THEIR USE AS PRODRUGS | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256191-A1 | Nitroaniline-based alkylating agents and their use as prodrugs | IDH3A, HIF1AN, IDH1 | KMT2A 708/4885MEN1 3633/4885HPGD 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.